Discovery And Receptor Profile — 2026 Update

By Editorial Desk · published 2026-02-18 · last reviewed 2026-04-05 · Faq

This is a working overview of 胰高血糖素受体, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-04-05. Anything still debated is marked as such rather than presented as settled.

Discovery and Receptor Profile

Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.

Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.

Analytical Methods and Material Handling

Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.

Material handling focuses on limiting degradation. Lyophilized powder is generally stored at reduced temperature, often around minus twenty degrees Celsius, protected from light and moisture. Once dissolved, the peptide is less stable and is commonly kept cold and used within a short window. Repeated freeze-thaw cycles promote aggregation and should be avoided. Buffers and pH influence stability, and solution conditions are usually selected to keep the peptide near neutral pH where degradation proceeds more slowly. These practices apply to laboratory reference material, not to clinical preparations.

Retatrutide at a glance

Retatrutide Background and Design

Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.

The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.

Related pages on this site

• Reliable index
• Gradual guide
• Quality review
• Robust review
• Practical update
• Adaptive reference
• Standard comparison
• Tracked playbook

瑞他鲁肽药理机制

该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。

临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。

Reference notes

It may also be possible to generate isotopes in the island of stability such as 298Fl in multi-nucleon transfer reactions in low-energy collisions of actinide nuclei (such as 238U and 248Cm). This inverse quasifission (partial fusion followed by fission, with a shift away from mass equilibrium that results in more asymmetric products) mechanism may provide a path to the island of stability if shell effects around Z = 114 are sufficiently strong, though lighter elements such as nobelium and seaborgium (Z = 102–106) are predicted to have higher yields. Preliminary studies of the 238U + 238U and 238U + 248Cm transfer reactions have failed to produce elements heavier than mendelevium (Z = 101), though the increased yield in the latter reaction suggests that the use of even heavier targets such as 254Es (if available) may enable production of superheavy elements. This result is supported by a later calculation suggesting that the yield of superheavy nuclides (with Z ≤ 109) will likely be higher in transfer reactions using heavier targets. A 2018 study of the 238U + 232Th reaction at the Texas A&M Cyclotron Institute by Sara Wuenschel et al. found several unknown alpha decays that may possibly be attributed to new, neutron-rich isotopes of superheavy elements with 104 < Z < 116, though further research is required to unambiguously determine the atomic number of the products. This result strongly suggests that shell effects have a significant influence on cross sections, and that the island of stability could possibly be reached in future experiments with transfer reactions.

This multidisciplinary approach allows researchers to identify vulnerable populations, characterize disparities in dementia incidence and outcomes, and evaluate interventions that may delay cognitive decline and improve quality of life for aging individuals. A defining strength of CAPAS is its emphasis on health equity and the study of historically underrepresented populations. Investigators examine racial, ethnic, geographic, and socioeconomic disparities in dementia risk, diagnosis, treatment, caregiving, and healthcare utilization, with particular attention to Hispanic, rural, and medically underserved communities throughout South Texas and the United States. By investigating the social determinants of brain health alongside biological mechanisms of aging, the Center provides critical insights into why dementia disproportionately affects certain populations and identifies opportunities to reduce inequities through targeted prevention strategies, public health initiatives, and healthcare policy. The Center also serves as an important resource for methodological innovation in population aging research. Faculty develop and apply advanced analytical approaches—including longitudinal data analysis, causal inference methods, machine learning, geospatial analysis, and health services research—to better understand the complex interactions among aging, chronic disease, cognitive decline, and social determinants of health.

Sample preparation for mass spectrometry is used for the optimization of a sample for analysis in a mass spectrometer (MS). Each ionization method has certain factors that must be considered for that method to be successful, such as volume, concentration, sample phase, and composition of the analyte solution. Quite possibly the most important consideration in sample preparation is knowing what phase the sample must be in for analysis to be successful. In some cases the analyte itself must be purified before entering the ion source. In other situations, the matrix, or everything in the solution surrounding the analyte, is the most important factor to consider and adjust. Often, sample preparation itself for mass spectrometry can be avoided by coupling mass spectrometry to a chromatography method, or some other form of separation before entering the mass spectrometer. In some cases, the analyte itself must be adjusted so that analysis is possible, such as in protein mass spectrometry, where usually the protein of interest is cleaved into peptides before analysis, either by in-gel digestion or by proteolysis in solution.

Sources: en.wikipedia.org

Reference notes

== Pharmacology == The basic pharmacophore, or active structure, of the fluoroquinolone class is based upon the quinoline ring system. Various substitutions made to the quinoline ring resulted in the development of numerous fluoroquinolone drugs. The addition of the fluorine atom at C-6 distinguishes the successive-generation fluoroquinolones from the first-generation quinolones, although examples are known that omit the atom while retaining antibacterial activity.

=== Others === Jessamine Lovelace — the ghost guardian of the London Institute. Also known as Jessamine Gray after her secret marriage to Tessa's brother Nate in The Infernal Devices. Jesse Blackthorn — Tatiana's deceased son and Grace Blackthorn's adoptive brother. His spirit can only be seen by his mother, Grace, and Lucie.

== History == Zalsupindole was first described in the scientific literature by David E. Olson and colleagues in 2021. It was developed by Olson's lab at the University of California, Davis and at his company Delix Therapeutics. The drug was first synthesized in 2019. It was initially described under the name AAZ-A-154 and then by the name DLX-001 before receiving the name zalsupindole.

Sources: en.wikipedia.org

Frequently asked questions